Filing Flows › Organogenesis Holdings (ORGO) › Q2 2026
Organogenesis Holdings (ORGO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Organogenesis Holdings (ORGO) reported revenue of $43.8M for the second quarter 2026 (Q2 2026), -57% from a year earlier and +18% from the quarter before. Operating margin was -116.5%, net loss $96.3M (220.0% of revenue).
Organogenesis Holdings, Q2 2026: revenue $43.8M (-57% year over year), operating margin -116.5%, net loss $96.3M, operating cash flow −$31.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $43.8M | +18% | -57% |
| Operating profit | −$51.0M | — | — |
| Net earnings | −$96.3M | — | — |
| Operating cash flow | −$31.7M | -250% | — |
What changed
Revenue was $43.8M in Q2 2026, down 57% year over year and up 18% from the previous quarter. Product was the largest line at 98% of revenue. Product lost $58.0M year over year (down 58%), 101% of the total change.
Operating costs exceeded revenue by $51.0M, an operating margin of -116.5%. Total costs fell 17% while revenue fell 57%. The fastest-growing cost line was Research & development (+76%). The quarter ended with a net loss of $96.3M, wider than the previous quarter's $53.2M loss.
Operating cash flow was −$31.7M. Non-cash charges added back $3.7M of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items added $57.9M. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$32.8M.
Questions
What was Organogenesis Holdings' revenue in the second quarter 2026?
Organogenesis Holdings (ORGO) reported revenue of $43.8M for the second quarter 2026 (Q2 2026), -57% from a year earlier and +18% from the quarter before.
Was Organogenesis Holdings profitable in the second quarter 2026?
Operating loss was $51.0M (-116.5% of revenue) and net loss $96.3M.